Logo
For Sales: 888.816.4721 | Contact Us

Upcoming Webinar to Discuss the Assessment of Tumor Burden and Clinical Benefit in Clinical Trials

August 28, 2016

Upcoming Webinar to Discuss the Assessment of Tumor Burden and Clinical Benefit in Clinical Trials

Boston, MA, August 28, 2016 – On Monday, September 19, 2016, Xtalks will host a complimentary webinar discussing the assessment of tumor burden and clinical benefit in immunotherapy clinical trials. Featured speakers include Dr. Klaus Noever, Senior Director of Medical Affair at WorldCare Clinical, and Dr. Ryan Sullivan, Assistant in Medicine and member of the Center for Melanoma and Teermer Center for Targeted Therapy at Massachusetts General Hospital and member of the Melanoma Program at Dana-Farber/Harvard Cancer Center. In a clinical trial, the treating investigator is responsible for deciding whether a trial participant continues on study. An important determinant on treatment decisions in solid metastatic tumors is the time course of lesion evolution as assessed by imaging using criteria such as the Response Evaluation Criteria in Solid Tumors (RECIST). According to RECIST, progressive disease (PD) is defined as a substantial increase in measurable or non-measurable disease or in the appearance of unequivocal new disease. Progressive disease suggests that a treatment is ineffective and therefore should be discontinued. RECIST has become the standard tumor assessment criterion for cytotoxic drugs and is accepted by regulatory agencies for evaluation of best overall response and time to progression as efficacy endpoints. With immunotherapy, deciding on whether to continue treatment may become subjective and idiosyncratic. For large international trials where experience levels and treatment standards vary, a large degree of assessment heterogeneity can be introduced. In order to mitigate the concern, a central review committee can be established that takes into account clinical benefit, adverse events, and imaging results. This webinar will give an overview of endpoint assessment as it relates to RECIST, irRC, and clinical benefit in the setting of cancer immunotherapy. Recommendations on when and how to apply each criterion will be reviewed as will case histories illustrating the clinical decision-making needed to determine if a patient should continue treatment. For more information or to register for this free webinar visit: Tumor Burden and Clinical Benefit Assessment in Immunotherapy Clinical Trials

About WorldCare Clinical

WorldCare Clinical is a global imaging CRO that employs scientific expertise, innovative technology, and operational excellence to maximize the precision and accuracy of a blinded independent central review of Phase I – IV clinical trial data. The company has worked with thousands of sites in more than 60 countries. WCC’s robust technology platform processes over 250 million images annually (CT, MRI, X-Ray, Echo, US, PET). Originally founded in 1992 by the Massachusetts General Hospital (MGH) Department of Radiology, WorldCare continues to maintain a strategic relationship with the Harvard Hospital System as well as other leading academic institutions.


For more information on WCC's services, please visit our website at wcclinical.com or contact:

Thomas O'Donnell

todonnell@wcclinical.com

(513) 924-5183

About Xtalks

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, please visit their website at www.xtalks.com